In Stock, Ready to Ship!
$300.00
99% Pure | USA Made | Multi DoseFOXO4-DRI is a synthetic peptide designed to disrupt the interaction between FOXO4 and p53, prompting targeted clearance of senescent cells in cell culture and animal models. Researchers use FOXO4-DRI to study cellular aging, senescence-associated secretory phenotype (SASP) modulation, and longevity signaling. Each 10 mg vial is USA-manufactured and tested to ≥99% purity, with endotoxin <0.1 EU/mg—ideal for your peptide-driven aging research.
Peptides are not ready to use. Must purchase BAC water for reconstitution.
FOXO4-DRI binds FOXO4, freeing p53 to trigger apoptosis specifically in β-galactosidase–positive senescent cells, modeling targeted cell-cleanup protocols.
Treatment with FOXO4-DRI lowers levels of inflammatory SASP factors (IL-6, IL-8) in fibroblast cultures, providing a tool to study inflammation in aging.
In endothelial and epithelial assays, FOXO4-DRI enhances markers of healthy mitochondrial function and stress resistance, supporting lifespan-extension research.
FOXO4-DRI influences p53-mediated pathways to balance DNA repair and apoptosis in cell-stress models, aiding studies of genotoxic resilience.
Concentrations from 100 nM to 5 µM reveal FOXO4-DRI’s senolytic potency and define optimal windows for protocol design.
Reconstitute in Sterile Water for Injection (SWFI) or Bacteriostatic Water (BAC). Store lyophilized at –20 °C; keep reconstituted solutions at 2–8 °C and use within 7 days to preserve ≥98% integrity.
FOXO4-DRI is a “designed-retro-inverso” peptide that mimics the FOXO4 protein’s binding region in reverse sequence and D-amino-acid form. This design enables it to enter cells and competitively displace FOXO4 from p53, selectively driving senescent cells into programmed cell death. It’s used in preclinical aging and tissue-regeneration models to study the impact of senescent-cell removal on tissue function.
Researchers choose FOXO4-DRI for its unmatched ability to target senescent cells without harming normal proliferating cells. Its retro-inverso design delivers enhanced stability in culture and in vivo, while rigorous purity testing ensures reproducible results. FOXO4-DRI provides a precise, scalable approach for labs exploring anti-aging, regenerative medicine, and cell-stress response protocols.
Unlike broad-spectrum senolytic compounds, FOXO4-DRI offers molecular specificity by disrupting a single protein–protein interaction (FOXO4:p53) to induce apoptosis only in senescent cells. Its D-amino-acid retro-inverso configuration grants exceptional resistance to proteolytic degradation, ensuring consistent activity throughout your experiments. FOXO4-DRI is the go-to peptide for clean, targeted senescence research.
FOXO4-DRI is a designed-retro-inverso peptide that disrupts the FOXO4:p53 interaction to selectively clear senescent cells in preclinical aging models.
It enters cells, displaces FOXO4 from p53, and triggers apoptosis only in β-galactosidase–positive senescent cells, preserving healthy cells.
Commonly used in studies of cellular senescence, SASP (senescence-associated secretory phenotype) modulation, and longevity-pathway assays.
Dissolve in Sterile Water for Injection (SWFI) or Bacteriostatic Water (BAC) according to your protocol, then gently mix until fully solubilized.
Store lyophilized FOXO4-DRI at –20 °C; keep reconstituted solutions at 2–8 °C and use within 7 days to maintain ≥ 98% peptide integrity.
In vitro protocols often span 100 nM to 5 µM, with dose–response curves used to pinpoint optimal senolytic activity.
Yes. Researchers frequently pair it with antioxidants or regenerative peptides (e.g., Epithalon, GHK-Cu) to study combined anti-aging effects.
Designed for specificity, FOXO4-DRI triggers apoptosis only in senescent cells, leaving proliferating cells largely unaffected in controlled studies.
No—FOXO4-DRI is strictly for research use only and is not approved for human or veterinary applications.
Real Peptides offers FOXO4-DRI that’s USA-manufactured, ISO-certified, tested to ≥ 99% purity, and endotoxin-screened for reliable research outcomes.
Don't hestitate to contact us
End of Content.
